• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by BiomX Inc. (Amendment)

    2/2/24 5:07:42 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    SC 13G/A 1 s13ga_012224-biomxinc.htm SCHEDULE 13G/A

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
    (Rule 13d-102)
     
    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. 1)1
     
     
    BiomX Inc.
    (Name of Issuer)
     
     
    Common Stock, $.0001 par value
    (Title of Class of Securities)
     
    09090D103
    (CUSIP Number)
     
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [ ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [ ] Rule 13d-1(d)

     

    1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     
     

     


    CUSIP No. 09090D103
    13G Page 2 of 5

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson

     

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    New Jersey

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 2,113,402
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 2,113,402
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,113,402
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.6% (1)
    12. TYPE OF REPORTING PERSON CO
                 

     

    (1) Based on 45,979,930 shares of Common Stock outstanding as of December 5, 2023, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

     
     

     


    CUSIP No. 09090D103
    13G Page 3 of 5

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (VOLUNTARY)

     

    Johnson & Johnson Innovation-JJDC, Inc.

     

     

    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)       [ ]

    (b)       [ ]

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5. SOLE VOTING POWER -0-
    6. SHARED VOTING POWER 2,113,402
    7. SOLE DISPOSITIVE POWER -0-
    8. SHARED DISPOSITIVE POWER 2,113,402
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,113,402
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [  ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.6%
    12. TYPE OF REPORTING PERSON CO
                       

     

    (1) Based on 45,979,930 shares of Common Stock outstanding as of December 5, 2023, as reported in the Issuer’s Registration Statement on Form S-3 filed with the Securities and Exchange Commission on December 7, 2023.

     

     

     
     

     


    CUSIP No. 09090D103
    13G Page 4 of 5

     

     

    AMENDMENT NO. 1 TO SCHEDULE 13G (FINAL AMENDMENT)

     

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on November 26, 2019 (the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.

     

    The following Items of the Schedule 13G are hereby amended and restated to read in their entirety as follows:

     

    Item 1(b). Address of Issuer’s Principal Executive Offices

     

    22 Einstein Street, Floor 4, Ness Ziona, Israel

     

    Item 2(c). Citizenship

     

    J&J: New Jersey

    JJDC: Delaware

     

    Item 4. Ownership

     

    (a) through (c):

     

    The information requested in these paragraphs is incorporated by reference to the cover pages to this Amendment No. 1 to Schedule 13G.

     

    Item 5. Ownership of Five Percent or Less of the Class

     

    If this statement is being filed to report the fact that the Reporting Persons have ceased to be the beneficial owners of more than five percent of the Common Stock, check the following: [X]

     

     

     
     

     


    CUSIP No. 09090D103
    13G Page 5 of 5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 2, 2024

     

     

    JOHNSON & JOHNSON

     

      By: /s/ Marc Larkins
      Name: Marc Larkins
      Title: Secretary
         
         
      JOHNSON & JOHNSON INNOVATION-JJDC, INC.
         
      By: /s/ Jill McManus
      Name: Jill McManus
      Title: Assistant Treasurer
    Get the next $PHGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Yeganeh Reuven

    3 - BiomX Inc. (0001739174) (Issuer)

    1/16/26 7:59:12 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by *Director by Deputization Flynn James E

    4 - BiomX Inc. (0001739174) (Issuer)

    4/23/25 5:49:02 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form 4 filed by Director Merril Gregory Louis

    4/A - BiomX Inc. (0001739174) (Issuer)

    4/21/25 8:24:29 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

    11/16/21 9:23:03 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chardan Capital reiterated coverage on BiomX with a new price target

    Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

    10/19/21 8:36:54 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. reiterated coverage on BiomX with a new price target

    HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

    10/18/21 12:27:44 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BiomX Issues Statement Regarding Recent Common Stock Trading Activity

    NESS ZIONA, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today issued a statement in response to recent unusual market activity in its common stock. The Company is not aware of any material developments in its business or affairs that have not been previously disclosed, nor, to its knowledge, of any other reason that would account for the recent unusual market activity in its common stock. NYSE American LLC has contacted the Company in accordance with its usual practice and has advised that the Company issue this statement

    1/27/26 1:41:26 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review

    Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial  BiomX continues to see potential in BX011, its phage program for Staphylococcus aureus (S. aureus) infections associated with diabetic foot infections (DFI). The Company is also implementing cost cutting measures, while evaluating strategic alternatives NESS ZIONA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) --  BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced its discontinuation of the ongoing Phase

    12/8/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    SEC Filings

    View All

    BiomX Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Financial Statements and Exhibits

    8-K - BiomX Inc. (0001739174) (Filer)

    2/10/26 4:29:14 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3 filed by BiomX Inc.

    S-3 - BiomX Inc. (0001739174) (Filer)

    2/9/26 4:33:55 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form PRE 14A filed by BiomX Inc.

    PRE 14A - BiomX Inc. (0001739174) (Filer)

    2/3/26 5:19:03 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Leadership Updates

    Live Leadership Updates

    View All

    BiomX Announces the Appointment of Susan Blum to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance

    4/18/24 8:00:00 AM ET
    $PHGE
    $PDLI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Telum Therapeutics appoints Dr. Subhendu Basu as CEO

    Dr. Basu brings over 20 years of deep technical and management expertise across academia and biotech.Dr. Basu joins the company to lead it into its next development phase, where he will focus on defining strategy, expanding the pipeline and driving corporate development.PAMPLONA, Spain and BARCELONA, Spain, March 19, 2024 /PRNewswire/ -- Telum Therapeutics ('Telum'), a pioneering biotechnology company specializing in the innovation of engineered phage endolysins as novel antibacterial agents to combat multidrug-resistant infections, is announcing the appointment of Subhendu Basu, PhD, as its new Chief Executive Officer. Dr. Basu comes to Telum with an impressive tenure of over two decades in

    3/19/24 5:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Announces the Appointment of Edward L. Williams to its Board of Directors

    CAMBRIDGE, Mass. and NESS ZIONA, Israel, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Edward L. Williams to its Board of Directors. "We are pleased to welcome Eddie to our Board of Directors," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "As a seasoned executive with extensive board experience, Eddie has successfully led the commercialization and marketing efforts across multiple therapeutic categories for global pharmaceutical companies. His insights, advice and experience will undoubtedly hel

    10/18/23 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    11/4/24 4:05:35 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    SC 13G/A - BiomX Inc. (0001739174) (Subject)

    10/28/24 4:01:32 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PHGE
    Financials

    Live finance-specific insights

    View All

    BiomX Announces $3.0 Million Private Placement

    NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. About the Private PlacementIn the Private Placement, the Company agreed to issue and sell shares of its Se

    12/29/25 8:00:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

    Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success  BiomX expects FDA feedback on BX004 clinical hold imminently; Enrollment and dosing of patients outside the U.S. are continuing in accordance with protocol Positive FDA feedback received in October provided guidance for potential Phase 3 development pathways of BX004 BiomX will host a conference call and webcast today at 8:30 AM ET NESS ZIONA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specif

    11/12/25 7:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BiomX to Report Third Quarter 2025 Financial Results and Program Updates on November 12, 2025

    NESS ZIONA, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it will report its third quarter 2025 financial results and program updates before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and a live audio webcast at 8:30 a.m. ET, to discuss the third quarter of 2025 financial results and provide program updates. To ensure you are connected prior to the beginning of the call, BiomX suggests registering a minimum of 5 minutes before the sta

    11/5/25 8:30:00 AM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care